Frederick National Laboratory for Cancer Research

The Protein Expression Laboratory produced recombinant proteins for an NCATS study that identified inhibitor for NSP14, a target for SARS-CoV-2 antiviral drug development. Learn more 👉 https://heyor.ca/NY7LUu

🌼 Spring has arrived at the Frederick National Laboratory! 🌼 On the first day of spring, the American Cancer Society Frederick County delivered fresh blooms across FNL locations, bringing hope and brightness to the season. Employees purchased daffodils, tulips, and potted daffodils as gifts for themselves, friends, or cancer patients in hospitals. Together, we raised $775 to support #CancerResearch and patient services! Thank you to our incredible FNL community for your generosity. #FNLProud #FrederickMD

Congratulations to Chief Science Officer Leonard Freedman, newly elected AAAS Fellow of the American Association for the Advancement of Science, one of the highest professional distinctions in the scientific community. Congrats to all of the 2024 #AAASFellows: https://lnkd.in/ejZ7zNKH

Register for the next Project Management Night Out seminar we're hosting with Hood College and PMI - Baltimore Chapter! ✅ 1 PDU in Power Skills ✅ Networking opportunity featuring heavy hors d'oeuvres ✅ Engaging seminar on project management Learn more: https://heyor.ca/vGKpKF Register now: https://heyor.ca/5LWnEC

Recent findings offer an opportunity for enhanced cancer treatment by better understanding the mutations of the cancer-causing protein mTOR. Scientists discovered a heretofore-unknown pocket in the protein's structure and used computer simulations to illuminate how mutated versions of mTOR contribute to cancer at a molecular level.

#DYK that we are home to unique scientific expertise and technological capabilities available nowhere else? More than 100 partners from academic, industry, & the non-profit sector have taken advantage of our technical services. Discover how we can support your study: https://heyor.ca/D2o0d1

A second drug candidate targeting RAS-related cancers developed by the RAS Initiative in partnership with BridgeBio Oncology Therapeutics (BBOT) and Lawrence Livermore National Laboratory has entered clinical trials. BBO-10203 blocks cancer-driving RAS-PI3K pathway, slowing tumor growth, and has shown unexpected activity in preclinical studies against a breast cancer cell line with HER2 amplification, unveiling new possibilities in breast cancer treatment. This drug development stemmed from years of research to overcome challenges in determining the 3D structure of RAS and PI3Ka bound to each other, using special techniques and "molecular glue" to stabilize the weak interaction between these proteins that fell apart using traditional methods. The realization of this compound and its first-in human clinical trial is a testament to multidisciplinary collaboration.

Apply to the Nanotechnology Characterization Laboratory's Assay Cascade Characterization Program! This resource is available to researchers in academia, industry, and government to enable further development of their #nanotechnology strategies towards clinical applications. Deadline to apply is September 2nd. To learn more, visit: https://heyor.ca/iHpfjK

Our scientists in the National Cancer Institute (NCI) RAS Initiative collaborate to develop treatments for RAS-driven cancers, and now have two investigational compounds in clinical trials. From protein production to assay development and structural discoveries, our research helps build the RAS knowledge base for investigators around the world dedicated to moving the field forward. Learn how we build community to make progress 👉 https://lnkd.in/gP_P69PX

To support local research teams and increase clinical trial enrollment, our Virtual Clinical Trials Office screens patients and provides data management support for the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis. Our team supports 11 clinical sites nationwide conducting cancer control and prevention protocols and cancer treatment trials. “We staff our team with clinical research professionals who have experience in onsite study coordination, sponsor monitoring, and auditing,” said Elaine Kulm, an FNL nurse administrator. “They have walked in the shoes of those they support.”